<p>高风险投资者对 Insmed (NASDAQ: INSM) 持悲观态度，零售交易者需要注意这一点。
\这一活动通过 Benzinga 对公开可用期权数据的跟踪引起了我们的注意。这些投资者的身份尚不确定，但 INSM 的如此重大变动通常意味着有人掌握了内部信息。</p>
<p>今天，Benzinga 的期权扫描仪发现了 8 笔 Insmed 的期权交易。这并不是一个典型的模式。</p>
<p>这些主要交易者的情绪分歧，12% 看涨，75% 看跌。在我们识别的所有期权中，有一笔看跌期权，金额为 27,207 美元，和 7 笔看涨期权，总计 347,874 美元。</p>
<h3>预测价格区间</h3>
<p>在评估交易量和未平仓合约后，显然主要市场参与者关注 Insmed 的价格区间在 32.5 美元到 200.0 美元之间，涵盖了过去三个月。</p>
<h3>交易量与未平仓合约发展</h3>
<p>检查交易量和未平仓合约为股票研究提供了重要见解。这些信息对于评估 Insmed 在特定行权价格的期权流动性和兴趣水平至关重要。以下是过去一个月 Insmed 重大交易中看涨和看跌期权的交易量和未平仓合约趋势快照，行权价格范围在 32.5 美元到 200.0 美元之间。</p>
<h3>Insmed 看涨和看跌期权交易量：30 天概览</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期权看涨图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png"/></p>
<h3>值得注意的期权活动：</h3>
<table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行权价格</strong></th>
<th><strong>总交易价格</strong></th>
<th align="right"><strong>未平仓合约</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.6</td>
<td>$7.0</td>
<td>$6.79</td>
<td>$200.00</td>
<td>$95.9K</td>
<td align="right">246</td>
<td align="right">137</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$143.3</td>
<td>$146.0</td>
<td>$32.50</td>
<td>$73.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$200.00</td>
<td>$58.1K</td>
<td align="right">246</td>
<td align="right">249</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$6.97</td>
<td>$200.00</td>
<td>$34.9K</td>
<td align="right">246</td>
<td align="right">364</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>中立</td>
<td>02/20/26</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.76</td>
<td>$200.00</td>
<td>$33.9K</td>
<td align="right">246</td>
<td align="right">471</td>
</tr>
</tbody>
</table>
<h3>关于 Insmed</h3>
<p>Insmed Inc 是一家生物制药公司，致力于改善严重和罕见疾病患者的生活。该公司的首个商业产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或没有替代治疗选择的抗菌药物组合的一部分。它还在开发 Brensocatib，一种用于支气管扩张症和其他中性粒细胞介导疾病的口服可逆性二肽基肽酶 1 抑制剂，以及用于与间质性肺病和肺动脉高压相关的肺动脉高压的吸入性特雷普斯汀前药。</p>
<h3>Insmed 当前市场状况</h3>
<ul>
<li>目前交易量为 476,194，INSM 的价格上涨了 1.45%，现为 180.0 美元。</li>
<li>RSI 指标显示该股票可能接近超卖状态。</li>
<li>预计收益发布将在 55 天后。</li>
</ul>
<h3>专业分析师对 Insmed 的评级</h3>
<p>5 位市场专家最近对该股票发布了评级，目标价格共识为 220.2 美元。</p>
<p><strong>在短短 20 天内将 1000 美元变成 1270 美元？</strong></p>
<p>一位拥有 20 年经验的期权交易员透露了他的单行图表技术，显示何时买入和卖出。复制他的交易，平均每 20 天获得 27% 的利润。点击这里获取访问权限。
* 一位来自高盛的分析师决定维持对 Insmed 的买入评级，目前目标价格为 225 美元。
* 一位来自 Cantor Fitzgerald 的分析师坚持对 Insmed 的增持评级，维持目标价格为 230 美元。
* 一位来自 Guggenheim 的分析师坚持对 Insmed 的买入评级，维持目标价格为 221 美元。
* 一位来自 RBC Capital 的分析师维持对 Insmed 的跑赢大盘评级，目标价格为 195 美元。
* 一位来自 HC Wainwright &amp; Co. 的分析师维持对 Insmed 的买入评级，目标价格为 230 美元。</p>
<p>与仅交易股票相比，期权是一种风险更高的资产，但它们具有更高的利润潜力。严肃的期权交易者通过每天学习、逐步进出交易、关注多个指标以及密切关注市场来管理这种风险。</p>
<p>如果您想及时了解 Insmed 的最新期权交易，Benzinga Pro 提供实时期权交易警报。</p>

INSM

<p>高风险投资者对 Insmed（NASDAQ:INSM）表现出看跌情绪，75% 的期权交易为看跌，12% 为看涨。Benzinga 的扫描器识别出 8 笔交易，关注价格区间为 32.5 美元至 200.0 美元。Insmed 的股票上涨 1.45%，现报 180.0 美元，分析师维持积极评级，目标价格在 195 美元至 230 美元之间。期权交易风险较高，但提供更高的利润潜力。Benzinga Pro 提供 Insmed 期权交易的实时警报</p>

<p>High-rolling investors have positioned themselves bearish on Insmed (NASDAQ: INSM), and it's important for retail traders to take note.
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in INSM often signals that someone has privileged information.</p>
<div class="lb-trans"><p>高风险投资者对 Insmed (NASDAQ: INSM) 持悲观态度，零售交易者需要注意这一点。
\这一活动通过 Benzinga 对公开可用期权数据的跟踪引起了我们的注意。这些投资者的身份尚不确定，但 INSM 的如此重大变动通常意味着有人掌握了内部信息。</p>
</div><p>Today, Benzinga's options scanner spotted 8 options trades for Insmed. This is not a typical pattern.</p>
<div class="lb-trans"><p>今天，Benzinga 的期权扫描仪发现了 8 笔 Insmed 的期权交易。这并不是一个典型的模式。</p>
</div><p>The sentiment among these major traders is split, with 12% bullish and 75% bearish. Among all the options we identified, there was one put, amounting to $27,207, and 7 calls, totaling $347,874.</p>
<div class="lb-trans"><p>这些主要交易者的情绪分歧，12% 看涨，75% 看跌。在我们识别的所有期权中，有一笔看跌期权，金额为 27,207 美元，和 7 笔看涨期权，总计 347,874 美元。</p>
</div><h3>Predicted Price Range</h3>
<div class="lb-trans"><h3>预测价格区间</h3>
</div><p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $32.5 and $200.0 for Insmed, spanning the last three months.</p>
<div class="lb-trans"><p>在评估交易量和未平仓合约后，显然主要市场参与者关注 Insmed 的价格区间在 32.5 美元到 200.0 美元之间，涵盖了过去三个月。</p>
</div><h3>Volume &amp; Open Interest Development</h3>
<div class="lb-trans"><h3>交易量与未平仓合约发展</h3>
</div><p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Insmed's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Insmed's significant trades, within a strike price range of $32.5 to $200.0, over the past month.</p>
<div class="lb-trans"><p>检查交易量和未平仓合约为股票研究提供了重要见解。这些信息对于评估 Insmed 在特定行权价格的期权流动性和兴趣水平至关重要。以下是过去一个月 Insmed 重大交易中看涨和看跌期权的交易量和未平仓合约趋势快照，行权价格范围在 32.5 美元到 200.0 美元之间。</p>
</div><h3>Insmed Call and Put Volume: 30-Day Overview</h3>
<div class="lb-trans"><h3>Insmed 看涨和看跌期权交易量：30 天概览</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2025/1766775710_0.png"/></p>
<h3>Noteworthy Options Activity:</h3>
<div class="lb-trans"><h3>值得注意的期权活动：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$7.6</td>
<td>$7.0</td>
<td>$6.79</td>
<td>$200.00</td>
<td>$95.9K</td>
<td align="right">246</td>
<td align="right">137</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$143.3</td>
<td>$146.0</td>
<td>$32.50</td>
<td>$73.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$200.00</td>
<td>$58.1K</td>
<td align="right">246</td>
<td align="right">249</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$6.97</td>
<td>$200.00</td>
<td>$34.9K</td>
<td align="right">246</td>
<td align="right">364</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/20/26</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.76</td>
<td>$200.00</td>
<td>$33.9K</td>
<td align="right">246</td>
<td align="right">471</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符号</strong></th>
<th><strong>看跌/看涨</strong></th>
<th><strong>交易类型</strong></th>
<th><strong>情绪</strong></th>
<th><strong>到期日</strong></th>
<th><strong>卖出价</strong></th>
<th><strong>买入价</strong></th>
<th><strong>价格</strong></th>
<th><strong>行权价格</strong></th>
<th><strong>总交易价格</strong></th>
<th align="right"><strong>未平仓合约</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.6</td>
<td>$7.0</td>
<td>$6.79</td>
<td>$200.00</td>
<td>$95.9K</td>
<td align="right">246</td>
<td align="right">137</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>交易</td>
<td>看涨</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$143.3</td>
<td>$146.0</td>
<td>$32.50</td>
<td>$73.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$200.00</td>
<td>$58.1K</td>
<td align="right">246</td>
<td align="right">249</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$6.97</td>
<td>$200.00</td>
<td>$34.9K</td>
<td align="right">246</td>
<td align="right">364</td>
</tr>
<tr>
<td>INSM</td>
<td>看涨</td>
<td>扫描</td>
<td>中立</td>
<td>02/20/26</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.76</td>
<td>$200.00</td>
<td>$33.9K</td>
<td align="right">246</td>
<td align="right">471</td>
</tr>
</tbody>
</table>
</div><h3>About Insmed</h3>
<div class="lb-trans"><h3>关于 Insmed</h3>
</div><p>Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.</p>
<div class="lb-trans"><p>Insmed Inc 是一家生物制药公司，致力于改善严重和罕见疾病患者的生活。该公司的首个商业产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或没有替代治疗选择的抗菌药物组合的一部分。它还在开发 Brensocatib，一种用于支气管扩张症和其他中性粒细胞介导疾病的口服可逆性二肽基肽酶 1 抑制剂，以及用于与间质性肺病和肺动脉高压相关的肺动脉高压的吸入性特雷普斯汀前药。</p>
</div><h3>Present Market Standing of Insmed</h3>
<div class="lb-trans"><h3>Insmed 当前市场状况</h3>
</div><ul>
<li>Currently trading with a volume of 476,194, the INSM's price is up by 1.45%, now at $180.0.</li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 55 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>目前交易量为 476,194，INSM 的价格上涨了 1.45%，现为 180.0 美元。</li>
<li>RSI 指标显示该股票可能接近超卖状态。</li>
<li>预计收益发布将在 55 天后。</li>
</ul>
</div><h3>Professional Analyst Ratings for Insmed</h3>
<div class="lb-trans"><h3>专业分析师对 Insmed 的评级</h3>
</div><p>5 market experts have recently issued ratings for this stock, with a consensus target price of $220.2.</p>
<div class="lb-trans"><p>5 位市场专家最近对该股票发布了评级，目标价格共识为 220.2 美元。</p>
</div><p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<div class="lb-trans"><p><strong>在短短 20 天内将 1000 美元变成 1270 美元？</strong></p>
</div><p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from Goldman Sachs has decided to maintain their Buy rating on Insmed, which currently sits at a price target of $225.
* An analyst from Cantor Fitzgerald persists with their Overweight rating on Insmed, maintaining a target price of $230.
* An analyst from Guggenheim persists with their Buy rating on Insmed, maintaining a target price of $221.
* Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Insmed, targeting a price of $195.
* Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Insmed, targeting a price of $230.</p>
<div class="lb-trans"><p>一位拥有 20 年经验的期权交易员透露了他的单行图表技术，显示何时买入和卖出。复制他的交易，平均每 20 天获得 27% 的利润。点击这里获取访问权限。
* 一位来自高盛的分析师决定维持对 Insmed 的买入评级，目前目标价格为 225 美元。
* 一位来自 Cantor Fitzgerald 的分析师坚持对 Insmed 的增持评级，维持目标价格为 230 美元。
* 一位来自 Guggenheim 的分析师坚持对 Insmed 的买入评级，维持目标价格为 221 美元。
* 一位来自 RBC Capital 的分析师维持对 Insmed 的跑赢大盘评级，目标价格为 195 美元。
* 一位来自 HC Wainwright &amp; Co. 的分析师维持对 Insmed 的买入评级，目标价格为 230 美元。</p>
</div><p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<div class="lb-trans"><p>与仅交易股票相比，期权是一种风险更高的资产，但它们具有更高的利润潜力。严肃的期权交易者通过每天学习、逐步进出交易、关注多个指标以及密切关注市场来管理这种风险。</p>
</div><p>If you want to stay updated on the latest options trades for Insmed, Benzinga Pro gives you real-time options trades alerts.</p>
<div class="lb-trans"><p>如果您想及时了解 Insmed 的最新期权交易，Benzinga Pro 提供实时期权交易警报。</p>
</div>

深入分析 Insmed 的期权市场动态